Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis
AbstractBackground Fibroblast growth factor 21 (FGF21) is deemed to play an important role in kidney outcomes, while the association between FGF21 and various kidney diseases remains largely unclear and inconsistent. Therefore, we conducted this meta-analysis to find out the role of FGF21 in various...
Main Authors: | Yong Guo, Ling Li, Shanbiao Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Renal Failure |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2179336 |
Similar Items
-
Fibroblast growth factor 21 attenuates salt-sensitive hypertension-induced nephropathy through anti-inflammation and anti-oxidation mechanism
by: Hua-Chun Weng, et al.
Published: (2021-11-01) -
Exploring the correlation between serum fibroblast growth factor-21 levels and Sarcopenia: a systematic review and meta-analysis
by: Hao Liu, et al.
Published: (2023-06-01) -
Fibroblast growth factor 21 and bone homeostasis
by: Yan Tang, et al.
Published: (2023-08-01) -
Sepsis and Fibroblast Growth Factor 21: A New Acute Phase Reactant?
by: Selcen Deveci, et al.
Published: (2022-09-01) -
Serum Fibroblast Growth Factor 21 in Patients with and without Pterygia
by: Gholamhosein Yaghoobi, et al.
Published: (2020-02-01)